115 related articles for article (PubMed ID: 17215077)
1. Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy.
Nicolini A; Carpi A; Rossi G
Cancer Lett; 2007 Jun; 251(2):330-8. PubMed ID: 17215077
[TBL] [Abstract][Full Text] [Related]
2. Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial.
Nicolini A; Carpi A
Biomed Pharmacother; 2005 Jun; 59(5):253-63. PubMed ID: 15913946
[TBL] [Abstract][Full Text] [Related]
3. Clinical and laboratory patterns during immune stimulation in hormone responsive metastatic breast cancer.
Nicolini A; Rossi G; Ferrari P; Carpi A
Biomed Pharmacother; 2014 Mar; 68(2):171-8. PubMed ID: 24491318
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
5. An immunotherapy schedule in endocrine-dependent metastatic breast cancer: correlation between clinical course and immunologic parameters.
Nicolini A; Carpi A; Rossi G
J Immunother; 2005; 28(3):276-9. PubMed ID: 15838385
[TBL] [Abstract][Full Text] [Related]
6. Investigations on cell-mediated immunity in patients with breast and ovarian carcinomas receiving a combination of chemotherapy and immunotherapy with thymopentin.
Mallmann P; Krebs D
Methods Find Exp Clin Pharmacol; 1990 Jun; 12(5):333-40. PubMed ID: 2232966
[TBL] [Abstract][Full Text] [Related]
7. Stage dependence of NK cell activity and its modulation by interleukin 2 in patients with breast cancer.
Konjević G; Spuzić I
Neoplasma; 1993; 40(2):81-5. PubMed ID: 8350959
[TBL] [Abstract][Full Text] [Related]
8. Maintenance immunotherapy in metastatic breast cancer.
Recchia F; Sica G; Candeloro G; Necozione S; Bisegna R; Bratta M; Rea S
Oncol Rep; 2008 Nov; 20(5):1173-9. PubMed ID: 18949418
[TBL] [Abstract][Full Text] [Related]
9. [The effect of adjuvant combined chemo/immunotherapy on immunological parameters and clinical course in patients with breast carcinoma].
Mallmann P; Krebs D
Zentralbl Gynakol; 1991; 113(12):697-706. PubMed ID: 1927119
[TBL] [Abstract][Full Text] [Related]
10. Cytokines in breast cancer.
Nicolini A; Carpi A; Rossi G
Cytokine Growth Factor Rev; 2006 Oct; 17(5):325-37. PubMed ID: 16931107
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
Donskov F
Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
[TBL] [Abstract][Full Text] [Related]
12. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
Maier S; Nimmrich I; Koenig T; Eppenberger-Castori S; Bohlmann I; Paradiso A; Spyratos F; Thomssen C; Mueller V; Nährig J; Schittulli F; Kates R; Lesche R; Schwope I; Kluth A; Marx A; Martens JW; Foekens JA; Schmitt M; Harbeck N;
Eur J Cancer; 2007 Jul; 43(11):1679-86. PubMed ID: 17601725
[TBL] [Abstract][Full Text] [Related]
13. [Immunotherapy in radical surgery of colorectal carcinoma].
Brivio F; Fumagalli L; Chiarelli M; Denova M; Bertolini A; Cetta M; Nespoli A
Chir Ital; 2007; 59(5):635-40. PubMed ID: 18019635
[TBL] [Abstract][Full Text] [Related]
14. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
[TBL] [Abstract][Full Text] [Related]
15. [The effect of sera of breast cancer patients on NK cell activity].
Konjević G; Spuzić I
Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
[TBL] [Abstract][Full Text] [Related]
16. Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2.
Svane IM; Pedersen AE; Nikolajsen K; Zocca MB
Vaccine; 2008 Aug; 26(36):4716-24. PubMed ID: 18616968
[TBL] [Abstract][Full Text] [Related]
17. [Assessment of changes in levels of interleukin 6 and C reactive protein in patients with breast tumors].
Zakrzewska I; Kozłowski L; Wojtukiewicz M
Pol Merkur Lekarski; 2003 Aug; 15(86):115-7. PubMed ID: 14648971
[TBL] [Abstract][Full Text] [Related]
18. Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response.
Helleman J; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; Meijer-van Gelder ME; Sieuwerts AM; Klijn JG; Sleijfer S; Foekens JA; Berns EM
Clin Cancer Res; 2008 Sep; 14(17):5555-64. PubMed ID: 18765548
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study.
Cazzaniga ME; Dogliotti L; Cascinu S; Barni S; Labianca R; Chiara S; Conte PF; Gasparini G; Pasetto L; Torri V
Oncology; 2006; 71(5-6):374-81. PubMed ID: 17785994
[TBL] [Abstract][Full Text] [Related]
20. The importance of distant metastases in hormone-sensitive breast cancer.
Rugo HS
Breast; 2008 Jan; 17 Suppl 1():S3-8. PubMed ID: 18279764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
